UNITED THERAPEUTICS Corp (UTHR) insider buying and selling
In the last 90 days at UNITED THERAPEUTICS Corp (UTHR), no insider made an open-market purchase and 2 insiders made 251 open-market sales worth $109.9M, as reported on SEC Form 4. All 251 sales were scheduled in advance or made to cover tax on vesting shares, so they say less about the insider's view of the stock. Over the last 12 months, 1 insider bought $864K of the stock, led by MARTINE A ROTHBLATT (CEO), who bought $864K on May 26, 2026; 5 insiders sold $492.3M, of which $159.5M was scheduled or tax-related.
This is the public summary. Create a free account to see UTHR’s AI Signal, the price chart with every insider trade plotted, and each insider’s track record.
Unlock UTHRRecent open-market insider trades
Trades by the same insider within a week are shown as one line.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| MARTINE A ROTHBLATT CEO | Open market sale 459 trades | 425,400 | avg. $557.36 | $237.1M | |
| JAN MALCOLM SVP | Open market sale | 325 | $550.59 | $179K | |
| PAUL A MAHON SVP | Open market sale 9 trades | 8,300 | avg. $552.56 | $4.6M | |
| JAMES EDGEMOND CFO | Open market sale 133 trades | 128,590 | avg. $561.44 | $72.2M | |
| PAUL A MAHON SVP | Open market sale 11 trades | 8,300 | avg. $541.55 | $4.5M | |
| PAUL A MAHON SVP | Open market sale 8 trades | 8,300 | avg. $547.07 | $4.5M | |
| MARTINE A ROTHBLATT CEO | Open market purchase | 1,500 | $575.96 | $864K | |
| PAUL A MAHON SVP | Open market sale 10 trades | 8,300 | avg. $562.82 | $4.7M | |
| Nilda Mesa SVP | Open market sale | 258 | $581.93 | $150K | |
| PAUL A MAHON SVP | Open market sale 8 trades | 8,300 | avg. $586.75 | $4.9M |
Scheduled and tax-related sales
Sales made under a pre-arranged 10b5-1 plan or to cover tax on vesting shares. They are listed separately because they are not a fresh decision to sell.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| MARTINE A ROTHBLATT CEO | 10b5-1 sale 231 trades | 198,460 | avg. $511.54 | $101.5M | |
| PAUL A MAHON CLO | 10b5-1 sale 11 trades | 8,300 | avg. $482.03 | $4.0M | |
| PAUL A MAHON CLO | 10b5-1 sale 9 trades | 8,300 | avg. $523.14 | $4.3M | |
| MARTINE A ROTHBLATT CEO | 10b5-1 sale 97 trades | 85,140 | avg. $530.70 | $45.2M | |
| PAUL A MAHON CLO | 10b5-1 sale 8 trades | 8,300 | avg. $533.69 | $4.4M |
What the UTHR insider trades really mean
The table above is the public summary. With an Insider Intel account you get the analysis behind it, for UNITED THERAPEUTICS Corp and every other stock we track:
UTHR's AI Signal score
One score from six weighted factors, with the full breakdown behind it, so you can see whether the buying is a real signal.
Unlock with a free accountEvery trade on the price chart
See each UTHR insider purchase and sale plotted on the chart, with the gain or loss on every one since.
Unlock with a free accountInsider track records
Is MARTINE A ROTHBLATT worth following? See their grade, win rate and average return on past purchases.
Unlock with a free accountAnalysts vs insiders
The consensus rating and price target next to the insider activity. Do the analysts agree?
Unlock with a free accountTrading windows
See when UTHR insiders are likely free to trade, shaded on the chart, so you know when to expect new filings.
Unlock with a free accountAlerts the moment they file
Get an email, Slack or in-app alert when a UTHR insider files, plus alerts for cluster buying.
Unlock with a free accountPlus AI summaries, the latest news for each stock, and an AI assistant you can ask questions about any of it.
Questions about UTHR insider trading
Who bought UNITED THERAPEUTICS Corp (UTHR) stock recently?
Insiders who bought UNITED THERAPEUTICS Corp stock on the open market in the last 12 months: MARTINE A ROTHBLATT ($864K). The most recent purchase was reported on May 26, 2026.
Are insiders buying or selling UTHR?
Over the last 12 months insiders were net sellers of UTHR on discretionary trades: $864K bought against $332.8M sold (scheduled and tax-related sales excluded).
What is a sell-to-cover or 10b5-1 sale?
A 10b5-1 sale is scheduled in advance under a pre-arranged plan, and a sell-to-cover sale is made to pay tax on vesting shares. Neither is a fresh decision to sell, so they say less about an insider's view than a discretionary sale.
Where does this data come from?
Officers, directors and large shareholders report their trades to the SEC on Form 4. This page lists the open-market purchases and sales by individual insiders from those public filings; funds and other institutions are not shown.
Other stocks with recent insider buying
- MAIR · Madison Air Solutions Corp$219.6M bought by insiders, last 90 days
- BRVE · Braveheart Bio, Inc.$39.5M bought by insiders, last 90 days
- PAMT · PAMT CORP$31.2M bought by insiders, last 90 days
- AUGO · Aura Minerals Inc.$22.7M bought by insiders, last 90 days
- ET · Energy Transfer$21.5M bought by insiders, last 90 days
- AAT · American Assets Trust, Inc.$18.2M bought by insiders, last 90 days
Create a free account and open its chart, score and alerts.
How to read this page
Officers, directors and large shareholders must report their trades in company shares to the SEC on Form 4. This page lists open-market purchases and sales by individual insiders: trades made on the stock exchange at the going price. Funds and other institutions are not shown here.
Information from SEC EDGAR Form 4 filings, shown for general information only. It is not financial advice and does not recommend buying or selling any security. Trades are shown by transaction date and may be reported up to two business days later.